Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

154.58
-0.3500-0.23%
Post-market: 153.90-0.6801-0.44%19:57 EDT
Volume:8.64M
Turnover:1.33B
Market Cap:371.93B
PE:17.20
High:154.90
Open:154.32
Low:152.45
Close:154.93
Loading ...

J&J: Total Company U.S. Economic Impact Estimated to Be More Than $100 Bln per Year

THOMSON REUTERS
·
21 Mar

J&J: Includes Four Planned New Manufacturing Facilities, With Ground-Breaking Today in North Carolina on $2 Bln+ Facility

THOMSON REUTERS
·
21 Mar

Johnson & Johnson - North Carolina Facility to Support 5,000 Jobs During Construction, Create 500 Positions

THOMSON REUTERS
·
21 Mar

Johnson & Johnson's Tremfya Receives US FDA Approval for Crohn's Disease

MT Newswires Live
·
21 Mar

FDA approves Johnson & Johnson’s TREMFYA in Crohn’s disease

TIPRANKS
·
21 Mar

BRIEF-US FDA Approves TREMFYA® (Guselkumab), The First And Only IL-23 Inhibitor Offering Both Subcutaneous And Intravenous Induction Options, For Adult Patients With Moderately To Severely Active Crohn's Disease

Reuters
·
21 Mar

U.S. FDA Approves Tremfya® (Guselkumab), the First and Only Il-23 Inhibitor Offering Both Subcutaneous and Intravenous Induction Options, for Adult Patients With Moderately to Severely Active Crohn's Disease

THOMSON REUTERS
·
21 Mar

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

GlobeNewswire
·
21 Mar

VGS ETF: The case for geographical diversification

MotleyFool
·
21 Mar

Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib) Significantly Outperforms Standard of Care in First-Line Egfr-Mutated Lung Cancer With Compelling New Data at Elcc 2025

THOMSON REUTERS
·
20 Mar

JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease

Zacks
·
19 Mar

The Zacks Analyst Blog Highlights Visa, Johnson & Johnson, Thermo Fisher and AMREP

Zacks
·
19 Mar

Top Stock Reports for Visa, Johnson & Johnson & Thermo Fisher Scientific

Zacks
·
19 Mar

Johnson & Johnson (NYSE:JNJ) Gains FDA Fast Track For Nipocalimab In Treating Sjogren's Disease

Simply Wall St.
·
19 Mar

Johnson & Johnson Says US FDA Grants Fast Track Designation for Sjogren's Disease Treatment

MT Newswires Live
·
18 Mar

Nipocalimab, the First and Only Investigational Treatment to Be Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults With Moderate-to-Severe SjÖGren's Disease, Has NOW Received Fast Track Designation

THOMSON REUTERS
·
18 Mar

J&J: Actively Enrolling Patients in Phase 3 Daffodil Study

THOMSON REUTERS
·
18 Mar

Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation

PR Newswire
·
18 Mar

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

ACCESS Newswire
·
18 Mar

Jim Cramer Says Johnson & Johnson (JNJ) Stock Could Fall to $160 Level

Insider Monkey
·
18 Mar